KRAS and colorectal cancer: Point mutations in the KRAS gene are present in approximately 35–45% of colorectal cancers (Dinu et al. 2014; Tan and Du 2012), and serve as a negative predictive factor of response to anti-EGFR therapy (Lievre et al. 2006).